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Objectives. This study investigated the effects of hormonal
therapy on large arterial properties.
Background. Arterial stiffness is an emerging risk marker for
coronary heart disease and is potentially modifiable. Postmeno-
pausal use of hormonal therapy is associated with a lower risk of
coronary heart disease.
Methods. Total systemic arterial compliance (SAC) and pulse
wave velocity (PWV) were determined in 26 premenopausal and 52
postmenopausal women, 26 of whom were taking hormonal ther-
apy.
Results. Arterial compliance was greater in the premenopausal
group (mean 6 SEM 0.57 6 0.04 arbitrary compliance units
[ACU]) than in the postmenopausal group not taking hormonal
therapy (0.26 6 0.02 ACU, p 5 0.001). Postmenopausal women
taking hormonal therapy had a significantly increased total SAC
compared with women not taking hormonal therapy (0.43 6 0.02
vs. 0.26 6 0.02 ACU, p 5 0.001). PWV in the aortofemoral region
in the premenopausal women was 6.0 6 0.2 vs. 8.9 6 0.3 m/s (p <
0.001) in untreated postmenopausal women. However, postmeno-
pausal women taking hormonal therapy had a significantly lower
PWV than those not taking hormonal therapy (7.9 6 0.2 vs. 8.9 6
0.3 m/s, p 5 0.01). Eleven postmenopausal women had their
hormone replacement therapy withdrawn for 4 weeks, resulting in
a significant decrease in SAC and a significant increase in
aortofemoral PWV.
Conclusions. The increased SAC and decreased PWV in women
receiving hormonal therapy suggest that such therapy may de-
crease stiffness of the aorta and large arteries in postmenopausal
women, with potential benefit for age-related cardiovascular dis-
orders. The reduction of arterial compliance with age appears to
be altered with hormonal therapy.
(J Am Coll Cardiol 1997;30:350–6)
©1997 by the American College of Cardiology
Postmenopausal use of estrogen-containing hormonal therapy
appears to be beneficial in reducing the incidence of coronary
heart disease (1,2) and possibly stroke (3). It has recently been
shown (4,5) that postmenopausal women taking estrogens also
have significantly lower death rates than age-matched control
subjects who did not. The precise mechanisms responsible for
this beneficial effect are not established. Estrogens appear to
have beneficial effects on lipoprotein profiles (6); however it
has been estimated that estrogen-induced changes in lipopro-
tein levels account for only 25% to 50% of the observed risk
reduction (7), suggesting that additional factors may be in-
volved. There is evidence that estrogens exert a direct effect on
the vasculature (8–10). Receptors for sex steroids have been
identified in the human aorta, left atrial appendage, internal
carotid, internal mammary and coronary arteries and saphe-
nous veins (11–13).
A number of studies have shown increased stiffness of the
proximal arterial circulation in subjects with coronary heart
disease (14–19), although the presence of increased choles-
terol levels itself appears not to necessarily result in this
increase (14,20–22). The possibility has been raised that
proximal aortic stiffness is a modifiable target for therapy (23).
Prospective studies (24) have established that pulse pressure, a
surrogate measure of arterial stiffness, is an independent
predictor of future coronary events. Arterial stiffness, deter-
mined by pulse wave velocity, increases with age in both men
and women, but a study in 600 subjects (25) has indicated that,
whereas arterial compliance in premenopausal women is
greater than that in men of equivalent age, this difference is
lost in the postmenopausal years, with evidence of a rapid
decline in compliance in the perimenopausal period. A recent
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study in hypertensive women (26) has also found a rapid
change in compliance perimenopausally and has related this to
changes in endogenous estrogen levels. Loss of hormonal
modulation is a likely explanation for reduced arterial compli-
ance, or increased stiffness, in postmenopausal women. The
consequent change in left ventricular afterload and diastolic
perfusion may be causally related to the production of myo-
cardial ischemia (27,28). Long-term treatment with estrogen-
containing hormonal therapy may be expected to partially
reverse the increase in arterial stiffness and thereby contribute
to a lower incidence of myocardial ischemia, and preliminary
reports (29) have indicated a reduction in stiffness with short-
term intravenous administration of estrogenic compounds in a
group of six postmenopausal women. However, long-term
postmenopausal use of the synthetic steroid Tibolone, struc-
turally related to norethisterone, was found (30) not to alter
aortic compliance, as derived from aortic pulse wave velocity.
We examined the capacity of long-term treatment with
estrogen-containing therapy to influence the age-related de-
crease in compliance in postmenopausal women. We com-
pared measures of arterial stiffness in postmenopausal women
receiving hormonal therapy with those of untreated women of
comparable age as well as a group of younger women. In
addition, 11 postmenopausal women were restudied after a
1-month cessation of hormonal therapy. Measures were made
of regional as well as integrated or total arterial compliance.
Methods
Subjects. Participants in the study were recruited by adver-
tisements placed in clinical and nonclinical areas of our own
and associated institutions. Twenty-six postmenopausal women
(mean age 6 SEM 58 6 1 years, range 50 to 71) treated
continuously with estrogen for at least 1.5 years (mean dura-
tion of therapy 6.7 6 1.0 years) were studied and compared
with 26 age-matched women (59 6 1 years old, range 50 to 70)
not taking such therapy. All women in the hormonal therapy
group had commenced taking hormones after cessation of
regular menstrual cycles, whereas those not taking such ther-
apy had a minimum of 2 years since the last menstrual cycle
and were free of vasomotor symptoms associated with the
onset of menopause. Twenty-six young women (mean age 23 6
1 years, range 17 to 35) were also studied. All studies were
performed in the first week after menstruation.
No subjects in either the premenopausal or postmeno-
pausal groups had any known cardiovascular disease; none
were taking medication (other than hormonal therapy in the
postmenopausal group); none smoked cigarettes; and all were
healthy, as determined from clinical history and full physical
examination. None of the subjects were participating in phys-
ical fitness programs, and all gave informed consent for
participation in the study, which was performed with the
approval of the Alfred Hospital Ethics Committee.
Protocol. Height and weight were determined for all par-
ticipants. Blood pressure and heart rate measurements were
made at the time of arterial compliance assessments. Blood
samples were taken for measurement of total plasma, high and
low density lipoprotein cholesterol and triglyceride levels.
Hormonal therapy was withdrawn in 11 of the postmenopausal
women for 1 month, at which time arterial compliance mea-
surements were repeated.
Systemic arterial compliance. Systemic arterial compliance
(SAC) was determined using calculations based on the area
method, as described by Liu et al. (31). In our laboratory
(32,33), SAC is estimated by the measurement of aortic flow
using continuous wave Doppler velocimetry with simultaneous
carotid pressure waveform recording. The formula used for
calculation is
SAC 5 Ad/@R~Ps 2 Pd!#,
where Ad is the area under the diastolic portion of the blood
pressure waveform (from end-systole to end-diastole), R the
total peripheral resistance, Ps the end-systolic blood pressure
and Pd the end-diastolic blood pressure.
Continuous ascending aortic flow velocity was measured
using a hand-held Doppler flow velocimeter (MDI Multi-
Doplex, Huntleigh Technology, Cardiff, UK) placed in the
suprasternal notch. This device provides an analog signal
proportional to the instantaneous frequency determined by the
number of detected zero crossings per unit time of the
backscattered Doppler signal, which can be related by the
Doppler equation to flow in the ascending aorta (34). This
technique provides an average (approximately root-mean
square) value for flow, which differs from the method used in
clinical applications estimating maximal flow. Because the
derived numerical value for flow determined using zero-
crossing analysis will be less than that obtained invasively, we
chose to report our results in arbitrary compliance units (ACU
[dimensionally equal to ml/mm Hg]), arbitrary flow units (AFU
[dimensionally equivalent to liters/min]) and arbitrary resis-
tance units (ARU). Volume flow was calculated as the product
of average systolic flow and aortic root area measured by
two-dimensional echocardiography (Hewlett-Packard Sonos
1500).
Aortic root pressure was estimated by applanation tonom-
etry of the right carotid artery using a noninvasive Miller
Mikro-Tip pressure transducer (model SPT-301, Miller Instru-
ments). The pressures obtained by tonometry were calibrated
against brachial diastolic and mean pressure measurements
determined oscillometrically and made simultaneously using a
Dinamap vital signs monitor (model 1846SX, Critikon) at the
brachial artery (average of five blood pressure recordings per
person). Briefly, the brachial mean arterial pressure was
Abbreviations and Acronyms
ACU 5 arbitrary compliance units
AFU 5 arbitrary flow units
ARU 5 arbitrary resistance units
PWV 5 pulse wave velocity
SAC 5 systemic arterial compliance
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assigned the area under the carotid waveform, and the brachial
diastolic pressure was assigned the automatically determined
end-diastolic point on the carotid waveform. This allowed
calculation of carotid systolic pressure and, thus, estimation of
central pulse pressure. Comparison between carotid wave-
forms recorded by tonometry and direct intraaortic waveforms
recorded with a microtipped manometer has demonstrated the
similarity between these waveforms, with the detectable differ-
ence between them being a smaller carotid than aortic aug-
mentation index, a difference that would not affect the calcu-
lation of SAC, which is dependent only on the diastolic
component of the wave (35). In accord with this, there was a
close correspondence between SAC calculated from direct
intraaortic recordings and carotid tonometry (32). Both flow
and pressure signals were digitized at 200 Hz. Analysis was
performed using custom-written software (Pascal Turbo, Bor-
land International, Inc.). The value of SAC was determined for
each patient from 10 representative flow and pressure wave-
forms.
Pulse wave velocity. Pulse wave velocity (PWV), a measure
of arterial stiffness, was determined centrally from the carotid
to femoral artery and distally from the femoral to dorsalis
pedis artery. PWV over the trunk and leg was determined by
simultaneous applanation tonometry of the carotid and femo-
ral and femoral and dorsalis pedis arteries, respectively. Data
were digitized (2,000 Hz/channel) and acquired using custom-
written software (J.D. Cameron). The time of travel between
applanation points was calculated from the upstroke of the
systolic waveform detected as the maximum of the second
derivative. Distances from the carotid sampling site to the
manubrium sternum, manubrium sternum to the femoral
artery (AF), and femoral artery to the dorsalis pedis (FD) were
measured. The central PWV (aortofemoral) was calculated as AF 2 CA divided by the time interval between carotid and
femoral pulses (36). PWV in the leg was calculated as the
distance traversed (FD) divided by time taken.
Statistics. Data were tabulated and analyzed using SPSS
(6.1 Windows). Results are given as mean value 6 SEM.
Group comparisons were made by one-way analysis of variance
and the Scheffe´ test. Multiple regression, by stepped backward
and forward entry, was undertaken to investigate determinants
of SAC. Variables were entered if the respective F values had
a p value , 0.05 and were removed if they had a p value . 0.1.
Paired t tests were used to compare variables in the 11
postmenopausal women withdrawn from therapy for 1 month.
The level of significance used was p , 0.05.
Results
There were no significant differences in age; body mass
index; total serum cholesterol, high and low density lipoprotein
cholesterol and triglyceride levels; heart rate; or blood pres-
sure between postmenopausal women receiving and those not
receiving hormonal therapy (Table 1). In postmenopausal
women, SAC was 0.26 6 0.02 ACU in untreated women
compared with 0.43 6 0.02 ACU in women receiving treatment
(p , 0.001) (Fig. 1). Mean PWV over the aortofemoral region
Figure 1. SAC and PWV in premenopausal women (PM) and post-
menopausal women with (1HRT) and without hormonal therapy
(2HRT). PWV A-F 5 PWV over the aortofemoral region; PWV
F-D 5 PWV over the femorodorsalis pedis region. Data shown are
mean value 6 SEM. *Significant differences (p , 0.05).
Table 1. Group Characteristics
Premenopausal
Women
(n 5 26)
Postmenopausal Women*
No Hormonal
Therapy
(n 5 26)
Hormonal
Therapy
(n 5 26)
Age (yr) 23 6 1 59 6 1† 58 6 1‡
LDL-C (mmol/liter) 2.7 6 0.1 3.2 6 0.2 3.3 6 0.3‡
HDL-C (mmol/liter) 1.4 6 0.1 1.4 6 0.1 1.3 6 0.1
Triglycerides (mmol/liter) 1.1 6 0.2 1.3 6 0.1 1.5 6 0.1‡
SBP (mm Hg) 106 6 2 126 6 3† 119 6 3‡
MAP (mm Hg) 77 6 2 92 6 2† 88 6 2‡
DBP (mm Hg) 63 6 2 71 6 1† 69 6 2
BMI (kg/m2) 22.7 6 0.7 27.0 6 1.4† 26.7 6 0.9‡
HR (beats/min) 64 6 2 67 6 1 68 6 2
*p 5 NS for all comparisons between the postmenopausal groups. †Pre-
menopausal versus postmenopausal women not receiving hormonal therapy.
‡Premenopausal women versus postmenopausal women receiving hormonal
therapy. Data presented are mean value 6 SEM. All pressures are peripheral
brachial pressures. BMI 5 body mass index; DBP 5 diastolic blood pressure;
HDL-C 5 high density lipoprotein cholesterol; HR 5 heart rate; LDL-C 5 low
density lipoprotein cholesterol; MAP 5 mean arterial blood pressure; SBP 5
systolic blood pressure.
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was significantly lower in women taking hormonal therapy
(7.9 6 0.2 vs. 8.9 6 0.3 m/s, p 5 0.01) (Fig. 1). Consistent with
these findings was the lower central pulse pressure in the group
taking hormonal therapy (Table 2). However, there were no
differences in either cardiac output or total peripheral resis-
tance between the two postmenopausal groups (Table 2).
PWV in the leg was lower in postmenopausal women with than
in those without hormonal therapy, but the difference failed to
achieve statistical significance (8.1 6 0.3 vs. 8.8 6 0.3 m/s) (Fig.
1). PWV is related to SAC (PWV } 1/=SAC), and we found
that PWV in the aortofemoral region correlated better with
1/=SAC (r 5 0.48, p 5 0.001) than did PWV in the leg (r 5
0.28, p 5 0.02).
Premenopausal women had significantly lower body mass
index; blood pressure; and total serum cholesterol, low density
cholesterol and triglyceride levels than postmenopausal
women, but there was no difference in heart rate. SAC in
premenopausal women (0.57 6 0.04 ACU) was significantly
higher than in either of the postmenopausal groups. Similarly,
PWV over the trunk (6.0 6 0.2 m/s) was significantly lower
than in either of the postmenopausal groups. Central pulse
pressure and total peripheral resistance in the premenopausal
women were not different from that in the postmenopausal
women taking hormonal therapy but were significantly lower
than that in the postmenopausal women not taking therapy
(Table 2). Cardiac output (Table 2) and PWV over the leg
(7.7 6 0.3 m/s) (Fig. 1) were not significantly different from
that in the postmenopausal women.
Women receiving hormonal therapy were then classified
into those receiving an estrogen only and those receiving both
an estrogen and a progestogen. Women receiving estrogen
only had an arterial compliance of 0.37 6 0.04 ACU compared
with 0.26 6 0.02 ACU in postmenopausal women not receiving
hormonal therapy (p 5 0.01) and 0.57 6 0.04 ACU (p , 0.01)
in premenopausal women. Women receiving a combination of
estrogen and progestogen had an arterial compliance of 0.46 6
0.03 ACU compared with 0.26 6 0.02 ACU in postmenopausal
women not receiving hormonal therapy (p , 0.001) and not
significantly different from that of premenopausal women
(0.57 6 0.04 ACU). SAC in women receiving estrogen only was
not significantly different from those receiving a combination
of an estrogen and a progestogen (0.37 6 0.04 vs. 0.46 6 0.03
ACU, p 5 0.07).
Multiple regression analysis, including age, presence of any
form of hormonal therapy, total cholesterol and triglyceride
levels and heart rate as independent variables and SAC as the
dependent variable in a stepwise model showed that age and
hormonal therapy were the only two independent factors
affecting SAC. These two factors accounted for 50% (r2 5
0.50) of the variance in SAC. Although compliance and mean
arterial pressure were inversely related in a univariate analysis
(r2 5 0.22, p , 0.001), neither mean, systolic nor diastolic
blood pressures were significant independent factors when
included in a multiple regression analysis.
In the 11 women in whom hormonal therapy was withdrawn
for 1 month, SAC was reduced from 0.43 6 0.04 to 0.33 6 0.02
ACU (p 5 0.008) (Fig. 2). PWV in the aortofemoral region
increased from 8.2 6 0.4 to 8.8 6 0.5 m/s (p 5 0.046) (Fig. 2),
and there was a trend toward elevation of central pulse
pressure (Table 3). However, there were no changes in mean
arterial, brachial systolic or diastolic pressures, total peripheral
resistance or cardiac output (Table 3). Leg PWV was also
elevated by the 4-week cessation of therapy, from 7.6 6 0.4 to
8.8 6 0.4 m/s (p 5 0.036) (Fig. 2).
Figure 2. SAC and PWV in 11 postmenopausal women receiving
hormonal therapy (1HRT) and after 1-month cessation of hormonal
therapy (2HRT4W). Other abbreviations as in Figure 1. Solid cir-
cles 5 mean value 6 SEM. *Significant differences (p , 0.05).
Table 2. Hemodynamic Variables
Premenopausal
Women
(n 5 26)
Postmenopausal Women
No Hormonal
Therapy
(n 5 26)
Hormonal
Therapy
(n 5 26)
CO (AFU) 1.10 6 0.08 0.97 6 0.09 1.09 6 0.08
Central PP (mm Hg) 43 6 1 56 6 4* 45 6 3†
Total PR (ARU) 14 6 1 22 6 2* 17 6 1
*Premenopausal versus postmenopausal women not receiving hormonal
therapy. †Hormonal therapy versus no hormonal therapy. Data presented are
mean value 6 SEM. AFU 5 arbitrary flow units; ARU 5 arbitrary resistance
units; CO 5 cardiac output; PP 5 pulse pressure; PR 5 peripheral resistance.
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Discussion
The present study demonstrates that long-term hormonal
therapy in postmenopausal women significantly reduces aor-
tofemoral PWV and increases SAC compared with age-
matched control subjects not using such therapy. SAC was
lower in the older women; however, this decline appeared to
be less in women receiving hormonal therapy. Both PWV and
SAC are dependent on arterial wall properties, with PWV
increasing and SAC decreasing with increased arterial stiffness
(37). We thus conclude that hormonal therapy reduces arterial
stiffness and support this contention further by the reduction in
SAC and elevation in aortofemoral PWV after a 4-week
cessation of therapy.
Factors influencing arterial compliance. Passive arterial
properties are dependent on mean distending pressure (37),
but there was no difference in mean arterial pressure between
the postmenopausal women with and without hormonal ther-
apy. However, differences in blood pressure may contribute to
reduced compliance in older compared with younger women.
Arterial compliance is affected by exercise training (32,33), but
none of our subjects were involved in fitness programs, and
mean heart rate, a crude measure of cardiovascular fitness, was
similar in the premenopausal and postmenopausal women with
and without hormonal therapy. Serum lipid levels affect endo-
thelial function in resistance vessels, although the effect on
conduit vessels is more controversial (14,20,38). However,
measures of total, low and high density lipoprotein cholesterol
were similar in both postmenopausal groups. Age, which is also
a major determinant of arterial compliance (25,37), was not
different between the two groups of postmenopausal women.
Mechanisms. The mechanisms for the effects of sex hor-
mones on arterial wall properties described here are not well
understood. The effects appear to be estrogen mediated be-
cause subgroup analysis revealed an effect on arterial proper-
ties in women taking estrogen alone. As discussed, the higher
arterial compliance of women receiving hormonal therapy than
age-matched control subjects not taking therapy was indepen-
dent of blood pressure. This difference therefore relates either
to a change in the loading conditions on the elastin and
collagen fibers or to structural changes in the vessel wall.
Estrogen may alter vessel wall loading conditions through
vasodilation by mechanisms that include potentiation of
endothelium-dependent vasodilation mediated by nitric oxide
(8–10,39–42). Dilation transfers vascular wall stress from the
collagen fibers to the more distensible elastin fibers, resulting
in a more compliant vasculature. Dilation may profoundly
influence proximal arterial compliance through direct effects
on the aorta and through the vasa vasorum as well (43). The
time course of the reduction in arterial compliance after
withdrawal of hormonal therapy for 4 weeks would be consis-
tent with a vasodilator mechanism.
Although changes in vascular loading conditions may un-
derlie the short-term effects of estrogen on arterial compli-
ance, longer term effects may be mediated by structural
vascular changes. Previous studies in experimental animals
have shown that estrogens can modulate the relative propor-
tions of collagen and elastin (44) and smooth muscle cell
numbers (45,46).
Peripheral compliance. Although SAC was significantly
higher, and PWV over the trunk significantly lower, in pre-
menopausal women, there was no significant difference be-
tween younger and older women in PWV over the leg. This
finding is consistent with previous evidence that aging-related
changes in the arterial circulation are more marked proximally
than distally (37,38,47). Similarly, the effects of hormonal
therapy in postmenopausal women were significant for PWV
over the trunk but not for PWV over the leg. The functional
compliance of the arterial circulation is predominantly con-
tained within the proximal arterial circulation (48), and in
keeping with previous findings (49) we found that 1/=SAC,
which is related to the Bramwell-Hill equation (49), where Co 5
=V dP/r dV (where Co 5 PWV; P 5 pressure; V 5 volume;
r 5 density), correlated better with PWV over the trunk than
over the leg. It would thus appear that the effects of hormonal
therapy are principally on the larger conduit vessels, which are
also the principal site for age-related changes. However,
previous studies (50,51) have shown effects of hormonal ther-
apy on carotid distensibility so that medium-sized conduit
vessels are also affected.
Compliance and cardiac function. Cardiac ventricular
function is dependent on the characteristics of the arterial
circulation, and aspects of ventricular function are different
with estrogen therapy (52). It is not possible at present to
discriminate between the relative contribution of direct effects
on the heart and those secondary to changes in arterial
function. In addition, changes in the stiffness of the proximal
circulation may also affect cardiac function indirectly through
changes in the operation of the baroreflex (33).
Conclusions. The present study demonstrates that hor-
monal therapy after menopause exerts a profound effect on the
properties of the proximal arterial circulation. This mechanism
may be important for the cardioprotective effect of hormonal
Table 3. Cessation of Hormonal Therapy
Postmenopausal Women*
Hormonal Therapy
(n 5 11)
After 4-wk
Cessation of
Hormonal Therapy
(n 5 11)
SBP (mm Hg) 122 6 4 125 6 6
DBP (mm Hg) 70 6 4 71 6 4
MAP (mm Hg) 90 6 4 92 6 5
Central PP (mm Hg) 45 6 3 49 6 4
CO (AFU) 1.15 6 0.44 1.12 6 0.11
Total PR (ARU) 18 6 2 18 6 2
*p 5 NS for all comparisons. Data presented are mean value 6 SEM. All
pressures are peripheral brachial pressures, unless otherwise stated. Abbrevia-
tions as in Tables 1 and 2.
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therapy and warrants further investigation through a prospec-
tive, placebo-controlled trial.
We thank Elizabeth Dewar, BSc, Leonie Johnston, SRN, CNN, SCM and Kaye
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